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The Role of miRNAs in Idiopathic 
Pulmonary Fibrosis
Koichi Takagi, Munekazu Yamakuchi, Teruto Hashiguchi  
and Hiromasa Inoue
Abstract
Idiopathic pulmonary fibrosis (IPF) is a genetic heterogeneous disease with 
high mortality and poor prognosis. IPF is characterized by persistent fibroblasts 
and relentless accumulation of collagen matrix. Epithelial-mesenchymal transition 
(EMT) and endothelial-to-mesenchymal transition (EndoMT) contribute to the 
progression of the fibrotic process. There are some therapeutic drugs that delay 
this progress, but eradicative medicine does not exist yet. MicroRNAs (miRNAs) 
are short single-stranded RNAs that regulate posttranscriptional silencing. Recent 
reports have shown that miRNAs play important roles in the development of IPF, 
as different expression levels of miRNAs in blood and lung tissue from IPF patients 
were closely associated with the occurrence of IPF disease. In this chapter, we will 
discuss the role of miRNAs in the pathogenesis, diagnosis, and treatment of IPF. In 
particular, we will focus on the regulation of EMT/EndoMT by miRNAs.
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1. Introduction
1.1 Overview of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a genetic heterogeneous disease with 
high mortality and poor prognosis that is characterized by progressive scarring of 
the pulmonary parenchyma, which leads to progressive loss of lung function with 
dyspnea and hypoxemia, and ultimately respiratory failure and death. IPF is a 
specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown 
cause. Disease pathogenesis involves airway tissue remodeling through the excess 
deposition of extracellular matrix (ECM) proteins and the formation of fibroblastic 
foci, evident by histology [1]. These events are occurred mainly by continuous dam-
age to the lung epithelium, which destroys the basement membrane and activates 
myofibroblasts. Myofibroblasts may not only come from resident or circulating 
fibroblasts but also be brought by epithelial cells transdifferentiated through 
epithelial-mesenchymal transition (EMT) [2]. Signaling through the TGF-β path-
way is thought to underlie many of these changes [3].
According to the 2018 joint statement by the American Thoracic Society (ATS), 
European Respiratory Society (ERS), Latin America Thoracic Association (ALAT), 
and Japanese Respiratory Society (JRS) [4], the diagnosis of IPF can be secured by 
exclusion of other known causes of interstitial lung disease (ILD) and either the 
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presence of high resolution computed tomography (HRCT) pattern of usual inter-
stitial pneumonia (UIP) or specific combinations of HRCT patterns and histopa-
thology patterns in patients subjected to lung tissue sampling. Any plausible cause 
of secondary interstitial involvement should be excluded by a thorough medical his-
tory and other procedures such as laboratory tests or bronchoalveolar lavage (BAL) 
when necessary. If a specific diagnosis is not made or no potential cause for ILD is 
identified, then clinical findings and HRCT are considered during multidisciplinary 
discussion among different experts (including clinicians, radiologists, pathologists, 
rheumatologists, and thoracic surgeons in selected cases) [4].
1.2 Overview of miRNAs
MicroRNAs (miRNAs) are short single-stranded RNA molecules of 19–25 
nucleotides in length that mediate posttranscriptional gene silencing of target genes 
[5]. MiRNAs have been recognized as a distinct class of small regulatory RNAs in 
multiple species that regulate a wide variety of functions such as cell proliferation, 
differentiation, apoptosis, stress response, and immune response [6–8]. MiRNAs 
regulate the onset and progress of a variety of diseases, such as cancer, infections, 
and atherosclerosis [9–11]. In lung diseases, many miRNAs contribute to the patho-
genesis. For instance, miR-424/503 regulates the progression of pulmonary hyper-
tension (PH) [12, 13]. miR-424/503 expression is reduced in the pulmonary artery 
of PH patients [13]. One of the targets of miR-424/503 is Rictor, and inhibition of 
miR-424/503 expression increased the expression of Rictor, leading to endothelial-
to-mesenchymal transition (EndoMT) and migration of pulmonary artery endo-
thelial cells [12]. In allergic asthma, miR-21, miR-126, and miR-145 are upregulated 
in multiple experimental asthma models [14–16], and miR-221 and miR-485-3p are 
upregulated in the peripheral blood of pediatric patients with asthma, compared 
with controls [17].
2. IPF and miRNAs
Profiling of miRNAs in the lung tissue from IPF patients was performed by 
different groups [18–22]. In IPF lungs, the expression of miR-21 and miR-155 was 
increased, whereas the expression of let-7a, miR-29, miR-30, and miR-101 was 
decreased [23–25]. MiR-21 expression was increased in the serum of IPF patients, 
and its levels correlated with a decrease in lung function [26]. In the miRNA expres-
sion profiling of sputum-derived exosomes from IPF patients, 21 miRNAs were dif-
ferentially expressed, among which seven (e.g., miR-142-3p and miR-33a-5p) were 
upregulated and 14 (e.g., Let-7d-5p) were downregulated [27]. In bronchoalveolar 
lavage fluid (BALF), miR-29a and miR-185 are downregulated in IPF patients [28, 29]. 
However, little is known about miRNA functions in IPF; much of the functional 
data has been inferred from chemically induced mouse IPF models. In the lungs of 
mouse IPF models, miR-21, miR-9, and miR-155 were increased [19, 21, 30], and 
miR-26, miR-101, miR-139, miR-200, miR-326, miR-489, miR-503, and miR-708 
were decreased [24, 31–37]. Furthermore, miR-21 expression was increased in 
myofibroblasts from IPF lungs, and its inhibition in mouse IPF models attenuated 
the disease severity [19]. The expression of miR-200 family members was reduced 
in mouse IPF models and restoration of miR-200c inhibited fibrosis [33]. Similarly, 
miR-26a was decreased in mouse IPF models and its inhibition caused pulmonary 
fibrosis, while overexpression repressed fibrotic disease [38]. Finally, miR-326 was 
decreased in mouse IPF models, and its administration mimicked inhibited TGF-β 
expression and attenuated fibrosis [34].
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3. The role of miRNAs in IPF-contributing cells
Epithelial cells communicate each other via adhesion molecules under physio-
logical condition. Among many adhesion molecules, E-cadherin plays an important 
role in maintaining tight junctions of epithelial cells. Recurrent and nonresolving 
injury to lung epithelial cells appears to be a key driver of pulmonary fibrosis. 
Recent studies have supported the concept that altered alveolar epithelial cell 
phenotypes, including those produced by increased endoplasmic reticulum stress, 
predispose to further epithelial cell injury and abnormal repair, facilitating the 
development of pulmonary fibrosis [39, 40], and thus suggested that the epithelial 
abnormalities/dysfunction underlying fibrosis should be referred to as reprogram-
ming. The ability of epithelial cells to change into mesenchymal cells through EMT 
plays an important role in the development of IPF.
Myofibroblasts and related mesenchymal cells are generally accepted as the cells 
predominantly responsible for fibrotic destruction/distortion of the lung in IPF 
[41]. Proliferation of fibroblasts and their differentiation into myofibroblasts are 
important in the development of IPF. The stage of mesenchymal cell differentia-
tion at which IPF myofibroblasts acquire hallmark pathological properties, the 
mechanisms underlying their pathological differentiation, and the roles of signals 
from epithelial cells, immune cells, and the matrix in this process has not been fully 
elucidated and requires further research.
The lung extracellular matrix (ECM) is comprised of collagens, elastin, 
glycoproteins, and proteoglycans, which serve as structural scaffolding for cells 
and provide the mechanical stability and elastic recoil necessary for proper lung 
function. In normal wound healing, myofibroblasts that produce ECM proteins are 
recruited during the active phase of repair, but are quickly removed via apoptosis 
once the repair process is underway. Most of the scar matrix subsequently resolves 
and is replaced by a more permanent tissue. In IPF, myofibroblasts are relatively 
resistant to apoptosis, and their persistence leads to excessive scarring [42]. A 
hallmark of IPF is the accumulation of myofibroblasts in clusters called fibroblastic 
foci and extensive ECM deposition within the interstitium, resulting in destruction 
of alveolar architecture.
Vascular muscularization driven by repeated small injury is the main patho-
genesis of PH, leading to the sustained fibrotic process of intima [43]. Different 
cellular processes have been described during pulmonary artery remodeling of 
PH-associated IPF, including endothelial dysfunction [44], EndoMT as a source of 
myofibroblasts [45], and pulmonary artery smooth muscle proliferation [46].
Monocytes and macrophages have a key role in regulating tissue repair 
and fibrosis, and several molecular pathways regulating their activity are 
being investigated as potential treatments for IPF. Macrophages possess many 
functions that would be expected to promote fibrosis, including fibroblast 
proliferation [47], regulation of ECM components [48], and secretion of pro-
fibrotic cytokines and growth factors. However, macrophages may also possess 
antifibrotic properties [47, 49]. Several studies have attributed these opposing 
functions to different macrophage populations distinguished along the lines of 
classical (M1) and alternative (M2) macrophage activation [50–52], with M1 
macrophages being antifibrotic and M2 macrophages being either profibrotic or 
regulatory.
Adaptive immune responses are involved in the pathological process in IPF 
patients. Infiltration of activated CD4+ T-cells into IPF lung is often observed 
before symptoms are developed [53]. Mature dendritic cells also infiltrate in the 
pulmonary parenchyma of IPF patients [54]. FoxP3 positive regulatory T-cells are 
diminished in both the circulation and BALF of IPF patients [55].
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3.1 Alveolar epithelial cells
miRNA microarray analysis of lung tissue from healthy controls and IPF patients 
showed that the expression of several let-7 family members was lower in IPF patients 
[18]. The human let-7 family includes 12 members (let-7-a1, a2, a3, b, c, d, e, f1, f2, 
g, 1, and miR-98), located on eight different homologous chromosomes [56]. In vitro 
inhibition of let-7d induced an increase in mesenchymal markers in lung epithelial 
cell lines. The High Mobility Group A2 (HMGA2) 3′ UTR has seven conserved sites 
complementary to the let-7 miRNA [57], and HMGA2 was significantly overex-
pressed in IPF lungs compared with controls [58]. In lung epithelial cell lines, let-7d 
regulated HMGA2 expression, and the increase in HMGA2 after TGF-β stimulation 
depended on inhibition of let-7 [18]. HMGA2 facilitates the transcription of SNAI1 
and TWIST, the transcriptional repressors of adherens, which are tight and desmo-
somal junction components, leading to reduced intracellular adhesion. Moreover, it 
is a mediator of TGF-β-induced EMT. Downregulation of let-7d also led to upregula-
tion of other fibrosis-relevant targets, such as RAS, insulin-like growth factor-1 
(IGF-1), and IGF-1 receptor, and thus to the profound and sustained changes in 
cellular phenotype that are indeed observed in IPF [18] (Figure 1).
The expression of miR-26a was significantly decreased in the lungs of mice 
following the administration of bleomycin [59]. Alignment of miR-26a with the 
HMGA2 3′UTR sequence revealed one potential conserved seed site. Transient 
introduction of miR-26a into A549 cells, a pulmonary epithelial cell line, led to a 
significant decrease in HMGA2. However, the reduction in miR-26a expression 
induced an obvious EMT phenotype in A549 cells together with a clear alteration in 
certain related proteins, including E-cadherin, vimentin, and α-SMA [59]. Loss of 
function of miR-26a facilitated lung epithelial cells to transform into myofibroblasts 
and induce pulmonary fibrosis in mice. Lin28D is also one of the conserved putative 
target genes of miR-26a. Inhibition of miR-26a induced Lin28D expression and 
caused an obvious EMT phenotype in A549 cells [31].
Figure 1. 
The role of miRNAs in alveolar epithelial cells for IPF.
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The miR-200 family has been suggested to regulate the progression of pulmo-
nary fibrosis by suppressing the EMT of alveolar epithelial cells (AECs). MiR-200 
family members correlated with E-cadherin expression in epithelial cells [60, 61] 
and negatively correlated with ZEB family expression, which has been implicated in 
EMT [62]. Furthermore, the miR-200 family members have been identified as EMT 
suppressors through direct targeting of ZEB1 and ZEB2 [63]. MiR-200 is downregu-
lated in the lungs of IPF patients and mouse IPF models [33]. In AECs, overexpres-
sion of miR-200, particularly miR-200b and miR-200c, attenuated TGF-β1-induced 
mesenchymal cell morphological characteristics and TGF-β1-repressed E-cadherin 
expression [33].
In fibrotic lungs, TGF-β1 is overexpressed in a broad range of cells, including 
epithelial cells, leading to the dysregulation of normal lung homeostasis by increas-
ing the synthesis and altering the balance of matrix metalloproteinases and their 
inhibitors [64]. MiR-326 targets the TGF-β1 3′UTR, and miR-326 levels inversely 
correlate with TGF-β1 protein levels in multiple human cell lines and in the lungs 
of mouse IPF models [34]. Restoration of miR-326 levels by intranasal delivery 
of miR-326 mimics was sufficient to inhibit TGF-β1 expression and attenuate the 
fibrotic response in the lungs of mouse IPF models [34]. Furthermore, miR-1343 
targets the 3′UTRs of TGFBR1 and TGFBR2 and attenuates EMT and fibrogenesis 
by inhibiting the TGF-β1 pathway in alveolar epithelial cell lines [65].
3.2 Fibroblasts and myofibroblasts
Several studies have shown that some miRNAs including miR-21, miR-29, miR-
101, miR-153, miR-154, miR-155, and miR-210 regulate the function of fibroblasts 
in the lungs (Figure 2).
The expression of miR-21 is increased in the lungs of mouse IPF models and 
of patients with IPF [19]. In mouse IPF models, miR-21 inhibition by lentiviruses 
encoding anti-miR-21 suppressed morphological markers of pulmonary fibrosis 
compared with controls [23]. TGF-β1 is the most important profibrogenic cytokine, 
which increases the expression of miR-21 through SMAD2/3/4 in lung fibroblasts 
[19] [66]. MiR-21 inhibition inversely regulates TGF-β1-induced ECM protein 
expression in human pulmonary fibroblast cell lines [23]. Smad7, which inhibits the 
proliferation of interstitial fibroblasts, is a direct target of miR-21 and negatively 
correlates with miR-21 in pulmonary fibroblasts [19].
Fibroblasts
Transdifferenaon
Proliferaon
ECM deposion
miR-21 ↑
Smad7
miR-29 ↓
Collagen
miR-101 ↓
NFATc2
miR-153 ↓
TGFβR2
miR-154 ↓
CDKN2B
miR-155 ↓
LXRα
miR-210 ↓
MNT
Myofibroblasts
Figure 2. 
The role of miRNAs in fibroblasts for IPF.
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Members of the miR-29 family, which consists of three mature members, 
miR-29a, miR-29b, and miR-29c, are among the most downregulated miRNAs in 
IPF lungs [66]. The expression of miR-29c is also decreased in the lungs of mouse 
IPF models [67]. MiR-29 has many target genes involved in the composition and 
regulation of ECM, thus downregulation of miR-29 is capable of contributing to 
excessive ECM deposition [20, 68]. In human fetal lung fibroblasts, miR-29 sup-
pression upregulated a series of genes, such as TGF-β1 regulated genes and adhesion 
molecules associated with the fibrotic phenotype [18].
MiR-101 is also one of the most downregulated miRNAs in fibrotic lungs from 
IPF patients and mouse IPF models [24]. Hypoxia-inducible factors (HIFs) con-
tribute to the pathogenesis of pulmonary fibrosis through Nuclear Factor-Activated 
T-cell (NFAT) c2 [69]. MiR-101 suppressed WNT5a-induced proliferation of lung 
fibroblasts via inhibition of NFATc2 signaling by targeting Frizzled receptor 4/6 
and attenuated bleomycin-induced pulmonary fibrosis in mouse IPF models [24].
MiR-153 is an intragenic miRNA that is embedded in genes encoding islet-asso-
ciated protein (IA)-2 and 2β. It has been shown to participate in the pathogenesis of 
neurodegenerative diseases [70] and inhibit the proliferation and invasion of many 
types of malignant cells [71]. Furthermore, TGF-β1 downregulates miR-153 expres-
sion in lung fibrosis, and miR-153 was downregulated in the fibrotic phase, which 
was characterized by excessive proliferation of fibroblasts and deposition of ECM 
in mouse IPF models [72]. However, miR-153 reduced the contractile and migratory 
activities of fibroblasts. TGFBR2, a transmembrane serine/threonine kinase recep-
tor for TGF-β, has been identified as a direct target of miR-153; moreover, miR-375 
regulates SMAD2/3 phosphorylation and the fibrogenic activity of lung fibroblasts 
through TGFBR2 inhibition [72].
The majority of increased miRNAs in IPF localizes to chromosome 14q32 and 
is enriched with members of the miR-154 family. TGF-β1 regulates the expression 
of miRNAs in the 14q32 cluster and induces the expression changes similar to those 
seen in IPF. TGF-β1 induces cell proliferation through CDK4 and CDKN2B, a CDK4 
inhibitor, which is a miR-154 target. Furthermore, TGF-β1-induced increases in 
proliferation were significantly reduced in the presence of miR-154 inhibitor in 
fibroblasts, and miR-154-induced changes in proliferation were mediated through 
the activation of the WNT/β-catenin pathway in fibroblasts [73].
MiR-155 is required for normal immune function [74]. Its overexpression is associ-
ated with inflammation, autoimmunity, and cancer [75], whereas miR-155-deficient 
mice develop age-related airway fibrosis [76]. Liver X receptor alpha (LXRα), which 
is an oxysterol-activated transcription factor, has a conserved 3′UTR seed-region 
sequence complementary to miR-155, and inhibition of LXRα ameliorated lung 
fibrosis in miR-155-deficient mice [77]. However, enforced expression of miR-155 
reduced the profibrotic phenotype of IPF and miR-155-deficient fibroblasts [77]. 
Thus, miR-155 attenuates lung fibrosis through inhibition of LXRα in lung fibroblasts.
The expression of miR-210 has been found to be increased in patients with 
rapidly progressive IPF, who typically have experienced hypoxia [22]. Consistently, 
miR-210 was upregulated in IPF fibroblasts in response to hypoxia, and its 
knockdown suppressed the hypoxia-induced proliferation of IPF fibroblasts. 
Furthermore, HIF-2α regulated miR-210 expression and miR-210-mediated pro-
liferation of IPF fibroblasts in response to hypoxia. Finally, miR-210 promoted IPF 
fibroblast proliferation through repression of its downstream target, MNT [78].
3.3 Endothelial cells
PH is frequently seen in IPF patients and is commonly attributed to hypoxic 
vasoconstriction and capillary destruction. Pathology findings include endothelial 
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proliferation and medial hypertrophy that exceed those expected in the setting 
of hypoxia [79] (Figure 3). HIF-1 activates the transcription of genes encoding 
angiogenic growth factors, including vascular endothelial growth factor (VEGF), 
angiopoietin (ANGPT), placental growth factor (PGF), and platelet-derived 
growth factor (PDGF), which are secreted by hypoxic cells and stimulate endothe-
lial cells, leading to angiogenesis. Furthermore, HIF-1 mediates hypoxia-induced 
phenotypic changes typical of EndoMT in endothelial cells [80].
ANGPT1 is a ligand for receptor tyrosine kinase Tie2 [81], which is expressed 
in endothelial cells [82]. ANGPT1-Tie2 signaling has been shown to be involved 
mainly in angiogenic activity and promoting maturation of blood vessels, and it 
is regulated by Akt and MAPK signaling [83, 84]. The activation of ANGPT1-Tie2 
signaling correlates with the severity of PH [85]. Mir-34a is downregulated in rat 
pulmonary arterial hypertension models [86], and ANGPT1 and Tie2 are potential 
targets of miR-34a, as they have a conserved miR-34a seed sequence in their 3′UTR 
[87]. Overexpression of miR-34a also downregulated the expression of PDGFRA, 
one of therapeutic targets of IPF, in pulmonary artery smooth muscle cells [86].
EndoMT has been proposed to be another potential source of myofibroblasts. 
In EndoMT, endothelial cells lose their own markers and obtain mesenchymal 
phenotype. Silencing of miR-155 directly increased RhoA expression and activ-
ity in endothelial cells and affected phosphorylation of the downstream LMK. A 
selective Rho kinase inhibitor partly suppressed EndoMT, strengthening the notion 
that RhoA plays a central role in EndoMT. Overexpression of miR-155 suppressed 
EndoMT, hence miR-155 functions as a negative regulator of RhoA signaling in 
TGF-β-induced EndoMT [88]. EndoMT has been considered as a source of myofi-
broblasts in PH [45], and miR-155 is downregulated in IPF lungs. Thus, miR-155 has 
been suggested to affect PH-associated IPF through inducing EndoMT.
3.4 Inflammatory cells
Macrophages possess many functions that would be expected to promote 
fibrosis, including regulation of fibroblast proliferation, recruitment, and activa-
tion, direct regulation of ECM components, and secretion of profibrotic cytokines 
and growth factors. There are two opposite characteristic types of functional 
macrophages; pro-inflammatory (M1) macrophages induced by toll-like receptor 
(TLR) and T helper type 1 (Th1) signals and anti-inflammatory (M2) macrophages 
Figure 3. 
The role of miRNAs in pulmonary endothelial cells for IPF.
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activated by Th2 signals [89] [90]. Th2 cytokines, IL-4 and IL-13 (IL-4/IL-13), con-
tribute to extensive tissue fibrosis in mouse models [91], and IL-4/IL-13-induced 
macrophages activate fibroblasts by secreting pro-fibrogenic cytokines. IL-4/IL-13 
induced CCL18 in lung macrophages of IPF patients, and secreted CCL18 increased 
the production of collagen from fibroblasts [92]. Many transcriptional factors, such 
as STAT (signal transducers and activator of transcription) family, regulate macro-
phage polarization. M1 macrophage polarization is controlled via STAT1, and M2 
macrophages activation is mediated by STAT6 [93]. To maintain STAT6 phosphory-
lation, M2 macrophages overcome strong expression of suppressor of cytokine 
signaling 1 (SOCS1), resulting in the prolongation of fibrogenesis (Figure 4).
IL-4/IL-13 induced miR-142-5p expression and suppressed miR-130a-3p expres-
sion in macrophages [94]. Transfection of macrophages with either miR-142-5p 
anti-sense oligonucleotides or miR-130-3p mimics significantly reduced the expres-
sion of M2 markers induced by IL-4 and regulated macrophage pro-fibrogenesis 
[94]. SOCS1 3′UTR has seven conserved sites complementary to miR-142-5p RNA, 
and PPARγ 3′UTR has seven conserved sites complementary to miR-130a-3p 
RNA. The expression of SOCS1 is reduced in IPF lungs, and bleomycin-induced 
lung fibrosis and inflammation were enhanced in SOCS1-deficient mice compared 
with WT mice [95]. Thus, miR-142-5p and miR-130a-3p regulate pulmonary 
fibrosis through SOCS1 and PPARγ in macrophages.
Downregulation of miR-185 has been demonstrated in IPF lung tissue and 
alveolar macrophages [29, 96]. MiR-185 inhibited cell growth and proliferation by 
directly targeting AKT1 [97]. Downregulation of miR-185 resulted in AKT activa-
tion via increased DNMT1 expression, leading to promoter hypermethylation 
and silencing of PTEN [77]. Moreover, miR-185 directly bound and degraded the 
3′UTR of AKT1 mRNA [98]. Finally, TGF-β1 inhibited the expression of miR-185 in 
macrophages, and thus TGF-β1 signaling has been suggested to induce proliferation 
and activation of macrophages through inhibition of miR-185 expression [98].
Some lymphocytic cytokines are considered profibrotic with direct effects on 
fibroblast and myofibroblast activity in IPF. Th1, Th2, and Th17 have been linked 
to IPF pathogenesis. The Th1 subset produces IL-1α, TNF-α, PDGF, and TGF-β1. 
The Th2 subset typical interleukins are IL-4 and IL-13, which are directly involved 
in fibroblast activation and ECM production. The Th17 subset indirectly promotes 
fibrosis by increasing TGF-β1 levels, and it is positively regulated by TGF-β1, 
Figure 4. 
The role of miRNAs in macrophages for IPF.
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creating a positive feedback loop [99]. In both BALF and the peripheral blood of 
IPF patients, the number of CD4 + CD25 + FOXP3+ regulatory T-cells (Tregs) is 
decreased compared with healthy people. Thus, Tregs’ numerical and functional 
deficiency may play a central role in the initial phases of IPF pathogenesis [55].
In CD4+ T cells, the level of miR-155 expression is positively associated with the 
expression of the Th2 cytokines, IL-5 and IL-13, and miR-155 suppresses inhibitors 
of cytokine production including SOCS1 [100]. However, Foxp3 inhibition signifi-
cantly decreased miR-146a expression in Tregs. The target gene of miR-146a is TNF 
receptor-associated factor 6 (TRAF6). Foxp3 and miR-146a have been suggested to 
regulate colonic inflammation and fibrosis by negatively regulating TRAF6 [101].
4. Conclusions
IPF is a heterogeneous disease that is affected and developed by various genetic 
backgrounds and environments. The recent development and approval of antifi-
brotic agents such as nintedanib and pirfenidone, both of which reduced the lung 
function decline rate in IPF patients in clinical trials, offer hope that it may be 
possible to alter the increased mortality associated with IPF; however, these thera-
peutic effects are not sufficient for curing the disease. To reveal new therapeutic 
IPF targets, genetic screening of IPF patients, including miRNAs, is an effective 
option. Over the past decade, the role of miRNAs in both promoting and alleviating 
chronic respiratory disease has become increasingly apparent. In IPF, some miRNAs 
have been indicated to be associated with EMT, EndoMT, fibrocyte differentiation, 
or ECM deposition. Investigation of miRNAs and their target genes associated 
with IPF may lead to new therapy. However, there have been some problems with 
applying miRNAs in the clinical scene: (1) multiple groups performing studies 
with similar experimental conditions have reported different and often contrasting 
results. Hence, collection methods and specimen parts need to be standardized, 
and better assays are needed for high-confidence miRNA measurements. (2) It is 
not clear whether miRNA misregulation is a direct cause of disease or an indirect 
result of gene regulatory processes. Most studies did not attempt to establish the 
necessity and sufficiency of the miRNA under investigation. (3) It is still difficult 
to interfere with miRNA expression in the human body, and it is possible that such 
interference will cause unexpected adverse reactions. (4) It has not been established 
how to introduce miRNAs into target cells safely and effectively, and the cost of this 
treatment will probably be high. Thus, miRNAs are still insufficient to be used as 
therapeutic targets in the clinical scene. Nevertheless, miRNAs may be important 
tools as IPF biomarkers. To use miRNAs clinically, further studies are necessary to 
elucidate the association between miRNAs and IPF.
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